Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The rationale for conducting this study is to evaluate the efficacy, tolerability, and safety
of rasagiline compared to placebo in levodopa-treated Parkinson's Disease (PD) Chinese
patients with motor fluctuations. Azilect® (Rasagiline) is indicated for the treatment of
idiopathic PD as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in
patients with end of dose fluctuations.